ClinicalTrials.gg
CompletedNCT00601523Updated Jun 9, 2014Results posted

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

A Phase 3 interventional study of Placebo and Pramipexole in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 119 sites in 15 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-06-09.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
511
Allocation
Non-randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
6th of 26
511 · median 224
Started
2008
the only one that year
Phase 3
11 of 26
none open now
Registered
14th of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 6th largest by enrollment, is the only one that started in 2008, is one of 11 in phase 3, and was the 14th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

The general aim of this study is to obtain long-term safety and tolerability data on pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have previously completed a pramipexole double-blind study in early PD (248.524(NCT00479401) or 248.636(NCT00558025) trial).

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completion of the double-blind trial 248.524 or 248.636
  2. Male or female patient with early idiopathic Parkinson´s disease (PD), and with a Modified Hoehn and Yahr stage of I to III.
  3. Patient willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
  4. Signed obtained before any study procedures are carried out (in accordance with International Conference on Harmonisation (ICH) - Good Clinical Practice (GCP) guidelines and local legislation).

Exclusion criteria

Exclusion criteria:

  1. Patients prematurely withdrawn from the double-blind trials 248.524 or 248.636.
  2. Atypical parkinsonian syndromes due to drugs,metabolic disorders, encephalitis or degenerative diseases.
  3. Any psychiatric disorder according to , fourth edition (DSM-IV) criteria that could prevent compliance or completion of the study and/or put the patient at risk if he/she takes part in the study.4.History of psychosis, except history of drug induced hallucinations.
  1. (ECG) abnormalities at baseline. 6.Clinically significant hypotension 7.Malignant melanoma or history of previously treated malignant melanoma. 8.Any other clinically significant disease, that could put the patient at risk or could prevent compliance or completion of the study. 9. Pregnancy or breast-feeding.
  1. Sexually active female of not using a medically approved method of for at least one month prior to the baseline and throughout the study.11 Serum levels of (AST) (SGOT), alanine aminotransferase (ALT) (SGPT), alkaline phosphatase or > 2 (ULN) at baseline 12. Patients with a \< 50 mL/min (estimated by the Cockcroft and Gault formula). 13. Motor complications under levodopa therapy (e.g. on-off phenomena, dyskinesia) at baseline.
  1. Any medication (including intra-muscular formulations) with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit. 15.Any of the following drugs within 4 weeks prior to baseline: methylphenidate, cinnarizine, amphetamines. 16. Flunarizine within 3 months prior to baseline.
  1. Known to pramipexole or its . 18. Drug abuse (including alcohol), according to investigator´s judgement, within 2 years prior to baseline.
  1. Participation in drug studies other than trials 248.524 and 248.636 or use of other investigational drug within one month or five times the half-life of the investigational drug prior to baseline.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
511 participants (actual)

Study arms

  • Active comparator
    Pramipexole

    Patient to receive Pramipexole ER 0.375-4.5 mg tabl form daily

    Drug: Pramipexole

  • Placebo comparator
    Placebo

    Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.

  • ER 0.375-4,5 mg

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events

    The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in early PD (248.524 (NCT00479401) or 248.636 (NCT00558025)). Therefore these items were considered as a safety evaluation

    Time frame: 80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)

Secondary outcomes

  1. Unified Parkinson's Disease Rating Scale (UPDRS) II+III Total Score: Change From Baseline

    UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

    Time frame: Open Label (OL) baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)

  2. Number of Patients With UPDRS II+III Response From OL Baseline at Week 80 (Patients From 248.524) or Week 72 (Patients From 248.636)

    A response means an improvement of \>=20% from OL baseline. UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

    Time frame: OL Baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)

  3. UPDRS I Total Score: Change From OL Baseline

    UPDRS I ranging from 0 (normal) to 16 (severe), measures Mentation, Behavior and Mood

    Time frame: OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)

  4. UPDRS II Total Score: Change From OL Baseline

    UPDRS II ranging from 0 (normal) to 52 (severe), measures activity of daily living.

    Time frame: OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)

  5. UPDRS III Total Score: Change From OL Baseline

    UPDRS III ranging from 0 (normal) to 108 (severe) measures motor symptoms

    Time frame: OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)

  6. Response in Clinical Global Impression of Improvement (CGI-I)

    Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least "much improved" were considered as responders. For patients previously treated with Pramipexole ER or Immediate Release (IR), all patients with no change to very much improved were considered as responders

    Time frame: OL Baseline and week 32 (patients from 248.524) or week 24 (patients from 248.636)

  7. Response in Patient Global Impression of Improvement (PGI-I)

    Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least "much better" were considered as responders. For patients previously treated with pramipexole (PPX) ER or IR, all patients with no change to very much better were considered as responders

    Time frame: OL Baseline and week 32 (patients from 248.524) or week 24 (patients from 248.636)

  8. Parkinson Fatigue Scale (PFS-16) : Change From OL Baseline

    PFS-16 ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD.

    Time frame: OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)

  9. Number of Patients Introducing L-Dopa Medication in OL Trial

    Number of patients requiring Levodopa supplementation during the study

    Time frame: 80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)

  10. L-Dopa Dose: Change From OL Baseline

    Change from open-label baseline in Levodopa dose

    Time frame: OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)

  11. Pramipexole Doses Respectively After 80 Weeks Compared to Pramipexole Doses at Week 8 for Previously 248.524 Patients and After 72 Weeks Compared to Pramipexole Doses at Week 0 for Previously 248.636 Patients

    Change from open-label baseline in Levodopa dose over the final 72 weeks of open-label assessment

    Time frame: Week 8 and week 80 (patients from 248.524) or week 0 and week 72 (patients from 248.636)

  12. Patient Preference Regarding Treatment Dosing

    Patients were surveyed on their preference for Once Daily dosing versus Three Times Daily dosing

    Time frame: 80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)

  13. Patient Rating of Convenience of Treatment Dosing

    Patients were surveyed on the convenience of Once Daily dosing versus Three Times Daily dosing

    Time frame: 80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)

07

Results

Posted Aug 25, 2011

Participant flow

Participant flow — Overall Study
MilestonePatients From 248.524Patients From 248.636
Started368143
Completed291117
Not completed7726
Withdrew: Adverse event4214
Withdrew: Lack of efficacy30
Withdrew: Protocol violation51
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject189
Withdrew: Other91

Outcome measures

SecondaryUnified Parkinson's Disease Rating Scale (UPDRS) II+III Total Score: Change From Baseline

UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

Time frame:
Open Label (OL) baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
Reported as:
Mean · Units of scale
Unified Parkinson's Disease Rating Scale (UPDRS) II+III Total Score: Change From Baseline
Units of scalePatients From 248.524Patients From 248.636
Unified Parkinson's Disease Rating Scale (UPDRS) II+III Total Score: Change From Baseline2.2 ± 9.51.5 ± 7.7
SecondaryNumber of Patients With UPDRS II+III Response From OL Baseline at Week 80 (Patients From 248.524) or Week 72 (Patients From 248.636)

A response means an improvement of \>=20% from OL baseline. UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

Time frame:
OL Baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
Reported as:
Number · Patients
Number of Patients With UPDRS II+III Response From OL Baseline at Week 80 (Patients From 248.524) or Week 72 (Patients From 248.636)
PatientsPatients From 248.524Patients From 248.636
Number of Patients With UPDRS II+III Response From OL Baseline at Week 80 (Patients From 248.524) or Week 72 (Patients From 248.636)7327
SecondaryUPDRS I Total Score: Change From OL Baseline

UPDRS I ranging from 0 (normal) to 16 (severe), measures Mentation, Behavior and Mood

Time frame:
OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
Reported as:
Mean · Units of scale
UPDRS I Total Score: Change From OL Baseline
Units of scalePatients From 248.524Patients From 248.636
UPDRS I Total Score: Change From OL Baseline0.3 ± 1.00.1 ± 1.3
SecondaryUPDRS II Total Score: Change From OL Baseline

UPDRS II ranging from 0 (normal) to 52 (severe), measures activity of daily living.

Time frame:
OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
Reported as:
Mean · Units of scale
UPDRS II Total Score: Change From OL Baseline
Units of scalePatients From 248.524Patients From 248.636
UPDRS II Total Score: Change From OL Baseline1.0 ± 3.20.6 ± 3.5
SecondaryUPDRS III Total Score: Change From OL Baseline

UPDRS III ranging from 0 (normal) to 108 (severe) measures motor symptoms

Time frame:
OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
Reported as:
Mean · Units of scale
UPDRS III Total Score: Change From OL Baseline
Units of scalePatients From 248.524Patients From 248.636
UPDRS III Total Score: Change From OL Baseline1.1 ± 7.20.9 ± 5.6
SecondaryResponse in Clinical Global Impression of Improvement (CGI-I)

Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least "much improved" were considered as responders. For patients previously treated with Pramipexole ER or Immediate Release (IR), all patients with no change to very much improved were considered as responders

Time frame:
OL Baseline and week 32 (patients from 248.524) or week 24 (patients from 248.636)
Reported as:
Number · Patients
Response in Clinical Global Impression of Improvement (CGI-I)
PatientsPatients From 248.524Patients From 248.636
Response in Clinical Global Impression of Improvement (CGI-I)284108
SecondaryResponse in Patient Global Impression of Improvement (PGI-I)

Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least "much better" were considered as responders. For patients previously treated with pramipexole (PPX) ER or IR, all patients with no change to very much better were considered as responders

Time frame:
OL Baseline and week 32 (patients from 248.524) or week 24 (patients from 248.636)
Reported as:
Number · Patients
Response in Patient Global Impression of Improvement (PGI-I)
PatientsPatients From 248.524Patients From 248.636
Response in Patient Global Impression of Improvement (PGI-I)265111
SecondaryParkinson Fatigue Scale (PFS-16) : Change From OL Baseline

PFS-16 ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD.

Time frame:
OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
Reported as:
Mean · Units of scale
Parkinson Fatigue Scale (PFS-16) : Change From OL Baseline
Units of scalePatients From 248.524Patients From 248.636
Parkinson Fatigue Scale (PFS-16) : Change From OL Baseline2.0 ± 12.52.2 ± 9.8
SecondaryNumber of Patients Introducing L-Dopa Medication in OL Trial

Number of patients requiring Levodopa supplementation during the study

Time frame:
80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)
Reported as:
Number · Patients
Number of Patients Introducing L-Dopa Medication in OL Trial
PatientsPatients From 248.524Patients From 248.636
No320117
Yes4721
SecondaryL-Dopa Dose: Change From OL Baseline

Change from open-label baseline in Levodopa dose

Time frame:
OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
Reported as:
Number · Patients
L-Dopa Dose: Change From OL Baseline
PatientsPatients From 248.524Patients From 248.636
Decrease40
Increase923
No change1941
SecondaryPramipexole Doses Respectively After 80 Weeks Compared to Pramipexole Doses at Week 8 for Previously 248.524 Patients and After 72 Weeks Compared to Pramipexole Doses at Week 0 for Previously 248.636 Patients

Change from open-label baseline in Levodopa dose over the final 72 weeks of open-label assessment

Time frame:
Week 8 and week 80 (patients from 248.524) or week 0 and week 72 (patients from 248.636)
Reported as:
Number · Patients
Pramipexole Doses Respectively After 80 Weeks Compared to Pramipexole Doses at Week 8 for Previously 248.524 Patients and After 72 Weeks Compared to Pramipexole Doses at Week 0 for Previously 248.636 Patients
PatientsPatients From 248.524Patients From 248.636
Decrease1019
Increase8244
No change15673
PrimaryPercentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events

The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in early PD (248.524 (NCT00479401) or 248.636 (NCT00558025)). Therefore these items were considered as a safety evaluation

Time frame:
80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)
Reported as:
Number · Percentage of participants
Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events
Percentage of participantsPatients From 248.524Patients From 248.636
Percentage of Patients with Adverse Events84.576.2
Percentage of Patients with Adverse Drug Reactions45.723.1
Percentage of Patients with Serious Adverse Events14.414.7
SecondaryPatient Preference Regarding Treatment Dosing

Patients were surveyed on their preference for Once Daily dosing versus Three Times Daily dosing

Time frame:
80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)
Reported as:
Number · participants
Patient Preference Regarding Treatment Dosing
participantsPatients From 248.524Patients From 248.636
Prefer Once Daily dosing27578
Prefer 3 Times Daily dosing91
No Preference74
Missing7655
SecondaryPatient Rating of Convenience of Treatment Dosing

Patients were surveyed on the convenience of Once Daily dosing versus Three Times Daily dosing

Time frame:
80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)
Reported as:
Number · participants
Patient Rating of Convenience of Treatment Dosing
participantsPatients From 248.524Patients From 248.636
Once Daily much more convenient19659
Once Daily more convenient7919
3 Times Daily much more convenient20
3 Times Daily more convenient61
No difference in preference74
Missing7755

Adverse events

Collected over Up to 80 weeks for patients from 248.524, Up to 72 weeks for patients from 248.636. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients From 248.524—53/368 (14.4%)214/368 (58.2%)
Patients From 248.636—21/143 (14.7%)62/143 (43.4%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventPatients From 248.524Patients From 248.636
FallInjury, poisoning and procedural complications3/3685/143
Femoral neck fractureInjury, poisoning and procedural complications0/3683/143
OsteoarthritisMusculoskeletal and connective tissue disorders1/3682/143
Parkinson's diseaseNervous system disorders2/3682/143
Myocardial infarctionCardiac disorders4/3681/143
AnaemiaBlood and lymphatic system disorders1/3681/143
Aortic valve incompetenceCardiac disorders0/3681/143
Atrioventricular block completeCardiac disorders0/3681/143
BradycardiaCardiac disorders0/3681/143
MalaiseGeneral disorders0/3681/143
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPatients From 248.524Patients From 248.636
SomnolenceNervous system disorders67/36810/143
Oedema peripheralGeneral disorders45/36815/143
Back painMusculoskeletal and connective tissue disorders40/36813/143
NauseaGastrointestinal disorders37/36810/143
DizzinessNervous system disorders32/3683/143
NasopharyngitisInfections and infestations29/3688/143
Parkinson's diseaseNervous system disorders7/36810/143
CataractEye disorders25/3687/143
ConstipationGastrointestinal disorders15/3689/143
HallucinationPsychiatric disorders8/3688/143

Baseline characteristics

Treated Set, all patients randomized and received treatment

Age, Continuous
Age, Continuous(Years)Patients From 248.524Patients From 248.636Total
Mean62.2 ± 9.264.0 ± 9.062.7 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Patients From 248.524Patients From 248.636Total
Female16462226
Male20481285
08

Study locations

119 sites
  • 248.633.01004 Boehringer Ingelheim Investigational Site
    Sun City, Arizona, United States
  • 248.633.01018 Boehringer Ingelheim Investigational Site
    Tempe, Arizona, United States
  • 248.633.01016 Boehringer Ingelheim Investigational Site
    La Jolla, California, United States
  • 248.633.01013 Boehringer Ingelheim Investigational Site
    Oxnard, California, United States
  • 248.633.01008 Boehringer Ingelheim Investigational Site
    Danbury, Connecticut, United States
  • 248.633.01010 Boehringer Ingelheim Investigational Site
    Boca Raton, Florida, United States
  • 248.633.01012 Boehringer Ingelheim Investigational Site
    Chicago, Illinois, United States
  • 248.633.01001 Boehringer Ingelheim Investigational Site
    Kansas City, Kansas, United States
  • 248.633.01005 Boehringer Ingelheim Investigational Site
    Commack, New York, United States
  • 248.633.01009 Boehringer Ingelheim Investigational Site
    Burlington, Vermont, United States
  • 248.633.43001 Boehringer Ingelheim Investigational Site
    Innsbruck, Austria
  • 248.633.43004 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 248.633.42004 Boehringer Ingelheim Investigational Site
    Olomouc, Czech Republic
  • 248.633.42003 Boehringer Ingelheim Investigational Site
    Pardubice, Czech Republic
  • 248.633.42001 Boehringer Ingelheim Investigational Site
    Praha, Czech Republic
  • 248.633.42002 Boehringer Ingelheim Investigational Site
    Rychnov nad Kneznou, Czech Republic
  • 248.633.35803 Boehringer Ingelheim Investigational Site
    Hyvinkää, Finland
  • 248.633.35801 Boehringer Ingelheim Investigational Site
    Oulu, Finland
  • 248.633.35802 Boehringer Ingelheim Investigational Site
    Tampere, Finland
  • 248.633.3303A Boehringer Ingelheim Investigational Site
    Aix en Provence, France
  • 248.633.3303B Boehringer Ingelheim Investigational Site
    Aix en Provence, France
  • 248.633.3303C Boehringer Ingelheim Investigational Site
    Aix en Provence, France
  • 248.633.3309A Boehringer Ingelheim Investigational Site
    Clermont Ferrand, France
  • 248.633.3309B Boehringer Ingelheim Investigational Site
    Clermont Ferrand, France
  • 248.633.3305A Boehringer Ingelheim Investigational Site
    Créteil, France
  • 248.633.3305B Boehringer Ingelheim Investigational Site
    Créteil, France
  • 248.633.3313A Boehringer Ingelheim Investigational Site
    Dijon cedex, France
  • 248.633.3304A Boehringer Ingelheim Investigational Site
    Evreux, France
  • 248.633.3308A Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 248.633.3308B Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 248.633.3308C Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 248.633.3308D Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 248.633.3308E Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 248.633.3302A Boehringer Ingelheim Investigational Site
    Marseille cedex 5, France
  • 248.633.3302B Boehringer Ingelheim Investigational Site
    Marseille cedex 5, France
  • 248.633.3302C Boehringer Ingelheim Investigational Site
    Marseille cedex 5, France
  • 248.633.3306A Boehringer Ingelheim Investigational Site
    Montpellier cédex 5, France
  • 248.633.3306B Boehringer Ingelheim Investigational Site
    Montpellier, France
  • 248.633.3306C Boehringer Ingelheim Investigational Site
    Montpellier, France
  • 248.633.3306D Boehringer Ingelheim Investigational Site
    Montpellier, France
  • 248.633.3306F Boehringer Ingelheim Investigational Site
    Montpellier, France
  • 248.633.3312A Boehringer Ingelheim Investigational Site
    Rouen, France
  • 248.633.3312B Boehringer Ingelheim Investigational Site
    Rouen, France
  • 248.633.3311A Boehringer Ingelheim Investigational Site
    Strasbourg, France
  • 248.633.3311B Boehringer Ingelheim Investigational Site
    Strasbourg, France
  • 248.633.3301C Boehringer Ingelheim Investigational Site
    Toulouse Cedex 7, France
  • 248.633.3301B Boehringer Ingelheim Investigational Site
    Toulouse cedex, France
  • 248.633.3301A Boehringer Ingelheim Investigational Site
    Toulouse, France
  • 248.633.3301D Boehringer Ingelheim Investigational Site
    Toulouse, France
  • 248.633.3301F Boehringer Ingelheim Investigational Site
    Toulouse, France
  • 248.633.3301G Boehringer Ingelheim Investigational Site
    Toulouse, France
  • 248.633.49009 Boehringer Ingelheim Investigational Site
    Achim bei Bremen, Germany
  • 248.633.49003 Boehringer Ingelheim Investigational Site
    Berlin-Steglitz, Germany
  • 248.633.49002 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.633.49004 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.633.49018 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.633.49019 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.633.49005 Boehringer Ingelheim Investigational Site
    Bochum, Germany
  • 248.633.49016 Boehringer Ingelheim Investigational Site
    Bochum, Germany
  • 248.633.49007 Boehringer Ingelheim Investigational Site
    Dresden, Germany
  • 248.633.49011 Boehringer Ingelheim Investigational Site
    Gera, Germany
  • 248.633.49017 Boehringer Ingelheim Investigational Site
    Karlsruhe, Germany
  • 248.633.49001 Boehringer Ingelheim Investigational Site
    Kassel, Germany
  • 248.633.49012 Boehringer Ingelheim Investigational Site
    Leipzig, Germany
  • 248.633.49013 Boehringer Ingelheim Investigational Site
    Marburg, Germany
  • 248.633.49015 Boehringer Ingelheim Investigational Site
    Unterhaching, Germany
  • 248.633.36007 Boehringer Ingelheim Investigational Site
    Eger, Hungary
  • 248.633.36005 Boehringer Ingelheim Investigational Site
    Györ, Hungary
  • 248.633.36008 Boehringer Ingelheim Investigational Site
    Miskolc, Hungary
  • 248.633.36004 Boehringer Ingelheim Investigational Site
    Sopron, Hungary
  • 248.633.36001 Boehringer Ingelheim Investigational Site
    Szeged, Hungary
  • 248.633.36006 Boehringer Ingelheim Investigational Site
    Szeged, Hungary
  • 248.633.36003 Boehringer Ingelheim Investigational Site
    Szombathely, Hungary
  • 248.633.36002 Boehringer Ingelheim Investigational Site
    Zalaegerszeg, Hungary
  • 248.633.91002 Boehringer Ingelheim Investigational Site
    Chennai, India
  • 248.633.91009 Boehringer Ingelheim Investigational Site
    Hyderabad, India
  • 248.633.91001 Boehringer Ingelheim Investigational Site
    Karnataka, India
  • 248.633.91005 Boehringer Ingelheim Investigational Site
    Maharashtra, India
  • 248.633.91007 Boehringer Ingelheim Investigational Site
    Maharashtra, India
  • 248.633.91004 Boehringer Ingelheim Investigational Site
    New Delhi, India
  • 248.633.91011 Boehringer Ingelheim Investigational Site
    Pune, India
  • 248.633.81010 Boehringer Ingelheim Investigational Site
    Aomori, Aomori, Japan
  • 248.633.81001 Boehringer Ingelheim Investigational Site
    Bunkyo-ku, Tokyo, Japan
  • 248.633.81005 Boehringer Ingelheim Investigational Site
    Fuchu, Tokyo, Japan
  • 248.633.81011 Boehringer Ingelheim Investigational Site
    Fujisawa, Kanagawa, Japan
  • 248.633.81013 Boehringer Ingelheim Investigational Site
    Fukuoka, Fukuoka, Japan
  • 248.633.81015 Boehringer Ingelheim Investigational Site
    Iwamizawa,Hokkaido, Japan
  • 248.633.81003 Boehringer Ingelheim Investigational Site
    Kodaira, Tokyo, Japan
  • 248.633.81014 Boehringer Ingelheim Investigational Site
    Kyoto, Kyoto, Japan
  • 248.633.81009 Boehringer Ingelheim Investigational Site
    Morioka, Iwate, Japan
  • 248.633.81008 Boehringer Ingelheim Investigational Site
    Okayama, Okayama, Japan
  • 248.633.81006 Boehringer Ingelheim Investigational Site
    Ota-ku, Tokyo, Japan
  • 248.633.81004 Boehringer Ingelheim Investigational Site
    Sagamihara, Kanagawa, Japan
  • 248.633.81007 Boehringer Ingelheim Investigational Site
    Shimogyo-ku, Kyoto, Kyoto, Japan
  • 248.633.81012 Boehringer Ingelheim Investigational Site
    Shiroishi, Miyagi, Japan
  • 248.633.81002 Boehringer Ingelheim Investigational Site
    Takamatsu, Kagawa, Japan
  • 248.633.60004 Boehringer Ingelheim Investigational Site
    Kuala Terengganu, Malaysia
  • 248.633.31002 Boehringer Ingelheim Investigational Site
    Geldrop, Netherlands
  • 248.633.31003 Boehringer Ingelheim Investigational Site
    Helmond, Netherlands
  • 248.633.31006 Boehringer Ingelheim Investigational Site
    Maastricht, Netherlands

Showing the first 100 of 119 sites across 15 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008 and a primary completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2008
First posted
Jan 28, 2008
Start
Jan 2008
Primary completionActual
Jun 2010
Results first posted
Aug 25, 2011
Last update
Jun 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00601523
Responsible party
Sponsor
First posted
Jan 28, 2008
Start date
Jan 2008
Primary completion
Jun 2010
Results posted
Aug 25, 2011
Last update
Jun 9, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion